The submission for treating paediatric plaque psoriasis is supported by outcomes from the Phase III PROTOSTAR study in ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics - ...

House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S.

J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients ...

Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug ...